Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines

1
Trends in the Pharmaceutical Industry and the
Potential Impact on Future Innovation and Access
to Medicines
Dr. Brian W Tempest www.briantempest.com Pharma
ceuticals Global Health Sussex University
Conference Centre , Brighton, UK 19 July 2013
2
Dr Brian Tempest advises Companies, Banks, High
Net Worth Individuals and Investment Funds on
their Strategy in the Emerging World based on
his wide experience in China, Japan, South East
Asia and India where he has lived for the last
decade. Brian has worked for Ranbaxy Laboratories
since 1995 holding the position of Managing
Director and Chief Executive Officer until 2005.
He was then Chief Mentor and Non Executive
Director until 2008 when he retired. He is one
of the few westerners to have led a Sensex Nifty
50 Indian blue Chip MNC and as a result has a
valuable insight into India. Brian has also
worked for Glaxo as Regional Director Far East
and Regional Director Middle East Africa from
1985 to 1992. Brian has worked in the
Pharmaceutical Industry for the last 41 years and
has managed Healthcare businesses in North
America, South America, Europe, Africa, Middle
East, Australasia, China, Japan and India. He has
also led many sessions at Investor Meetings held
around the world. He is now Independent Chairman
of Religare Capital Markets PLC , a Non Executive
Director of Fortis Healthcare the leading Asian
Healthcare Company, a Non Executive Director of
SRL the largest Indian Diagnostic Company and a
Non Executive Director of Glenmark
Pharmaceuticals. He is a member of the SCRIP
Global awards panel and is on the Editorial
Board of the Journal of Generic Medicines. Brian
speaks at global conferences and more information
on these presentations can be found on his
website www.briantempest.com. Brian has a PhD in
Polymer Chemistry from Lancaster University in
1971 and in 2009 he became Chairman of the
Advisory Board for the Lancaster University
Management School, UK. He is a Fellow of the
Royal Society of Medicine and a Fellow of the
Royal Society of Chemistry and is a Chartered
Chemist. He is now Chairman and Senior Partner
of Hale Tempest Co Ltd
3
Healthcare costs versus GDP Wages
4
Everybody Concerned about Health Costs
5
Increasing Generics Biosimilars
6
A Slide from a UK Headhunter
7
Pharma in Crisis Source Pharmatimes February
2013
8
Generics versus Big Pharma
9
Patent Cliff to 2018 source Evaluate Pharma,
Sandoz
10
Top 25 Global Generic Companies Source Generics
Bulletin 10 June 2011

• 
  

11
Products Going Off Patent in 2015 33bSource
Evaluate Pharma 14 February 2013
12
The Teva Future Standing Still Source RBC
Capital 12 December 2012
13
Global footprint of Watson/Actavis excluding
most of the developing world
14
Indian Generic Cos continue to growSource
Pharmatimes World News Feb 5 2013

• Many Indian Companies in 2013 showing a sales
  growth of gt20
• Indian Pharma Exports 2008-2012 around the World
  have shown a CGR of 19 in sales
• New Product Pipeline in USA ANDAs shows
  approvals from India in 2012 was 37 with 178
  out of a total of 476 and in 2011 33 with 144
  out of 431
• New ANDA filings of ANDAs in the USA from India
  indicate 51 in 2011 and 49 in 2010

15
Indias First Compulsory Licence after 3 years at
a high price Source Economic Times 13 March
2012

• 
  

16
More CLs on the way in India Source 29 March
2013
17
India Patent dismissed for EvergreeningSource
Financial Express 2 April 2013
18
Anti Cancer Drugs At Delhi Airport Source New
Delhi Airport 28 March 2013
19
But Indian Price Cuts source Hindustan Times 20
June 2013
20
Aggressive EU-India Bilateral FTA Source ET 27
March 2013
21
The Future of IP?

• In 2012 Big pharma had the best NCE year since
  1997
• There are 230b sales going off patent in
  2013-2018 but only half will be replaced by
  generics owing to biologics
• Big Pharma is finding the BRICS markets tough
• More CLs likely from the BRICS countries owing
  to evergreening or a very high price limiting
  access
• Do all patents need to be 20 years? The first USA
  patent law in 1790 was for 14 years.
• What is the point of a patent if only the rich
  can use it?

22
Thank You brian.tempest_at_clara.co.uk www.briantempe
st.com